Veritas In Silico Inc. (JP:130A) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. is expanding its global reach by securing a patent in Europe for its innovative method in RNA-targeted drug discovery. This strategic move is expected to enhance their proprietary drug discovery platform, ibVIS®, despite the patent having a minimal immediate impact on business performance. The company anticipates significant future progress from this development.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.